Neuronetics, Inc. (STIM) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Neuronetics, Inc. (STIM) Healthcare & Pipeline Overview

Neuronetics, Inc. specializes in neurohealth solutions, primarily the NeuroStar Advanced Therapy System for major depressive disorder. Leveraging transcranial magnetic stimulation, the company offers a non-invasive treatment option, positioning itself within the evolving landscape of mental health therapies and medical technology.

What Is the Investment Thesis for STIM?

Neuronetics, Inc. presents a focused investment opportunity within the neurohealth sector, primarily driven by the NeuroStar Advanced Therapy System. The company's gross margin of 48.0% indicates potential for profitability as adoption increases. Key value drivers include expanding the installed base of NeuroStar systems and increasing utilization rates among existing customers. Growth catalysts involve ongoing clinical trials exploring new indications for TMS therapy and strategic partnerships to broaden market access. However, investors should be aware of the company's negative profit margin of -24.5% and the competitive landscape, which includes pharmaceutical interventions and other neuromodulation technologies. Successful execution of its commercial strategy and continued innovation are crucial for Neuronetics to achieve sustainable growth and deliver shareholder value.

Based on FMP financials and quantitative analysis

STIM Key Highlights

Market capitalization of $211M reflects the company's current valuation in the medical technology sector.

• Gross margin of 48.0% indicates the profitability of Neuronetics' NeuroStar system and related services.
• Negative profit margin of -24.5% highlights the company's ongoing investments in research, development, and commercialization.
• Beta of 0.87 suggests that the stock's price is less volatile than the overall market.
• The company focuses on the NeuroStar Advanced Therapy System, a non-invasive treatment for major depressive disorder.

Who Are STIM's Competitors?

STIM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are STIM's Key Strengths?

Proprietary NeuroStar TMS technology.

• Direct sales and support network.
• Focus on non-invasive depression treatment.
• Established brand in neurostimulation.

What Are STIM's Weaknesses?

Negative profit margin.

• Reliance on a single product line.
• Limited market share compared to pharmaceutical treatments.
• High cost of NeuroStar system.

What Could Drive STIM Stock Higher?

Clinical trials evaluating the efficacy of TMS in treating other neurological and psychiatric conditions.

• Efforts to expand reimbursement coverage for NeuroStar therapy.
• Potential regulatory approvals for new indications of TMS therapy.
• Strategic partnerships to broaden market access and distribution.

What Are the Key Risks for STIM?

Financial-distress signal — its Altman Z-Score of -3.06 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Competition from pharmaceutical companies offering antidepressant medications.
• Reimbursement challenges from payers regarding coverage for NeuroStar therapy.
• Technological advancements by competitors leading to more effective or less expensive treatments.
• Dependence on the NeuroStar system as the primary revenue source.

What Are the Growth Opportunities for STIM?

• Expanding the NeuroStar Installed Base: Neuronetics has the opportunity to increase its revenue by expanding the number of NeuroStar systems installed in psychiatric practices and hospitals. This involves targeted sales and marketing efforts to reach new customers and demonstrate the clinical and economic benefits of the NeuroStar system. The market for TMS therapy is growing, driven by increasing awareness of depression and the limitations of traditional treatments. Capturing a larger share of this market requires Neuronetics to effectively compete with other TMS providers and alternative therapies. The timeline for this growth opportunity is ongoing, with continuous efforts to expand the installed base year over year.
• Increasing Utilization Rates: Neuronetics can drive revenue growth by increasing the utilization rates of existing NeuroStar systems. This involves providing ongoing training and support to healthcare providers to ensure they are effectively using the system and maximizing patient outcomes. Higher utilization rates also lead to increased sales of NeuroStar treatment sessions, which generate recurring revenue for the company. The market for TMS therapy is influenced by factors such as reimbursement policies and patient demand. Neuronetics can work with payers to improve reimbursement coverage and educate patients about the benefits of TMS therapy. The timeline for this growth opportunity is ongoing, with continuous efforts to improve utilization rates among existing customers.
• Exploring New Indications for TMS Therapy: Neuronetics is actively exploring new clinical applications for its TMS technology beyond major depressive disorder. This includes conducting clinical trials to evaluate the efficacy of TMS in treating other neurological and psychiatric conditions, such as anxiety, PTSD, and OCD. Successful expansion into new indications could significantly broaden the market opportunity for Neuronetics and drive revenue growth. The timeline for this growth opportunity depends on the progress of clinical trials and regulatory approvals. Neuronetics is committed to investing in research and development to unlock the full potential of its TMS technology.
• Strategic Partnerships and Collaborations: Neuronetics can accelerate its growth by forming strategic partnerships and collaborations with other healthcare companies, research institutions, and patient advocacy groups. This can involve co-marketing agreements, joint research projects, or distribution partnerships. Collaborating with established players in the healthcare industry can provide Neuronetics with access to new markets, technologies, and expertise. The timeline for this growth opportunity is opportunistic, with potential partnerships arising at any time. Neuronetics is actively seeking out strategic alliances that align with its mission and growth objectives.
• International Expansion: Neuronetics has the opportunity to expand its geographic reach by entering new international markets. This involves obtaining regulatory approvals for the NeuroStar system in foreign countries and establishing sales and distribution networks. The market for depression treatment is global, with significant unmet needs in many countries. Expanding internationally can provide Neuronetics with access to a larger customer base and drive revenue growth. The timeline for this growth opportunity depends on regulatory approvals and market entry strategies. Neuronetics is carefully evaluating potential international markets and developing plans for expansion.

What Are STIM's Competitive Advantages?

• Proprietary TMS technology with patents protecting its NeuroStar system.
• Established brand reputation in the neurostimulation therapy market.
• Direct sales and customer support team with expertise in TMS therapy.
• Growing installed base of NeuroStar systems creating recurring revenue streams.

What Does STIM Do?

Neuronetics, Inc., established in 2001 and headquartered in Malvern, Pennsylvania, is a commercial-stage medical technology company dedicated to designing, developing, and marketing innovative products for individuals grappling with neurohealth disorders. The company's flagship product, the NeuroStar Advanced Therapy System, represents a significant advancement in the treatment of major depressive disorder (MDD). This system provides a non-invasive, non-systemic, office-based treatment option for adult patients who have not achieved satisfactory improvement from prior antidepressant medication. The NeuroStar system employs transcranial magnetic stimulation (TMS) to deliver targeted pulses of MRI-strength magnetic fields. These pulses induce electrical currents in specific regions of the brain known to be associated with mood regulation. By stimulating these areas, the NeuroStar system aims to alleviate the symptoms of depression. Neuronetics markets and sells its NeuroStar systems and related services directly to psychiatrists and other healthcare providers through its dedicated sales and customer support teams. The company's focus on innovation and patient well-being has established it as a key player in the evolving field of neurostimulation therapies for mental health conditions. Neuronetics continues to explore new applications and enhancements for its NeuroStar technology, solidifying its commitment to improving the lives of individuals affected by neurohealth disorders.

What Products and Services Does STIM Offer?

• Designs and develops medical devices for neurohealth disorders.
• Markets the NeuroStar Advanced Therapy System.
• Provides a non-invasive treatment for major depressive disorder.
• Uses transcranial magnetic stimulation (TMS) technology.
• Sells products directly to psychiatrists and healthcare providers.
• Offers customer support and training for the NeuroStar system.
• Conducts clinical trials to explore new applications for TMS therapy.

How Does STIM Make Money?

• Sells NeuroStar Advanced Therapy Systems to psychiatric practices and hospitals.
• Generates revenue from NeuroStar treatment sessions.
• Provides ongoing training and support services to customers.
• Invests in research and development to expand the applications of TMS therapy.

What Industry Does STIM Operate In?

Neuronetics operates within the medical device industry, specifically focusing on neurostimulation therapies for mental health disorders. The market for depression treatment is substantial, with a growing demand for non-pharmacological interventions. The competitive landscape includes pharmaceutical companies offering antidepressant medications and other medical device companies developing alternative neuromodulation technologies. Neuronetics' NeuroStar system competes with other TMS devices and emerging therapies, requiring continuous innovation and effective marketing to maintain market share. The industry is also influenced by evolving clinical guidelines, reimbursement policies, and patient awareness of neurostimulation options.

Who Are STIM's Key Customers?

• Psychiatrists
• Mental health clinics
• Healthcare providers treating patients with major depressive disorder

Over the past six months, Neuronetics, Inc. insiders filed 21 SEC Form 4 transactions — 5 sales and 16 purchases. On net that is roughly 857K shares acquired (about $212K) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: Neuronetics, Inc.

Revenue for Neuronetics, Inc. came in at $41.6M during Q2 FY2026, a 20.6% improvement versus the preceding quarter. The company recorded a net loss of $3.4M, with diluted EPS of $-0.05. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, STIM averaged $-0.11 in diluted EPS.

STIM Valuation & Market Position

With a $211M market cap, Neuronetics, Inc. sits in the micro-cap segment of the market. Analyst price targets span from $5.00 to $5.00, with a consensus of $5.00. At the current price of $3.03, that implies approximately 65% upside potential. Relative to its peer group, STIM's quantitative score of 21/100 is below the peer average of 35/100.

Key Financial Metrics

Return on assets is -23.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.88 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -14.0%, the inverse of the P/E and a quick read on earnings relative to price.

Neuronetics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.06 places it in the distress zone, a signal of elevated financial risk.

Neuronetics, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 24.2% below estimates on average.

Company Profile

Neuronetics, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Malvern, US. The company is led by CEO Daniel L. Reuvers. STIM has traded publicly since 2018.

STIM Financials

STIM Latest News

STIM Analyst Consensus

STIM MoonshotScore

Neuronetics, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources